Cytokinetics (NASDAQ:CYTK – Get Rating) had its price objective raised by JMP Securities from $53.00 to $82.00 in a report released on Monday morning, Marketbeat.com reports. They currently have a market outperform rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently weighed in on CYTK. Piper Sandler upped their […]
